keyword
MENU ▼
Read by QxMD icon Read
search

ocriplasmin

keyword
https://www.readbyqxmd.com/read/27913441/size-and-vitreomacular-attachment-of-primary-full-thickness-macular-holes
#1
Elise Philippakis, Franck Amouyal, Aude Couturier, Elise Boulanger-Scemama, Alain Gaudric, Ramin Tadayoni
PURPOSE: To study the relationship between the size of primary full-thickness macular hole (MH) and the vitreomacular attachment status. DESIGN: Single-centre retrospective observational case series. METHODS: The records of 100 consecutive eyes operated for primary full-thickness MH were retrospectively reviewed. The vitreous status and MH diameter were assessed on the preoperative optical coherence tomography scans. MH were classified depending on the presence or absence of vitreomacular traction (VMT) and their size as small (<250 µm), medium (250-400 µm) and large (>400 µm), as suggested in the International VMT Study Group Classification...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27787446/impact-of-vitreoretinal-interface-architecture-on-successful-vitreomacular-traction-resolution-in-eyes-scheduled-for-intravitreal-ocriplasmin-therapy
#2
Christoph Paul, Christine Heun, Hans H Müller, Sascha Fauser, Hakan Kaymak, Sara Kazerounian, Walter Sekundo, Stefan Mennel, Carsten H Meyer, Steffen Schmitz-Valckenberg, Michael J Koss, Nicolas Feltgen, Thomas Bertelmann
PURPOSE: To evaluate the impact of the vitreoretinal interface architecture, in specific the angle between the posterior vitreous cortex and the internal limiting membrane, on vitreomacular traction (VMT) resolution in eyes treated with intravitreally injected ocriplasmin (Jetrea). METHODS: Retrospective, multicenter cohort study and exploratory data analysis. Spectral domain optical coherence tomography assessments were performed before scheduled ocriplasmin injections...
October 26, 2016: Retina
https://www.readbyqxmd.com/read/27786583/the-efficacy-and-safety-profile-of-ocriplasmin-in-vitreomacular-interface-disorders
#3
Mehrine Shaikh, John B Miller, Thanos D Papakostas, Deeba Husain
Vitreomacular adhesion (VMA) describes the adhesion of the posterior hyaloid face to the inner retina in any part of the macula. This can arise after incomplete separation of the posterior vitreous cortex from the macula during vitreous liquefaction. While the VMA may resolve spontaneously, a strong and persistent adhesion can lead to a variety of anatomical changes, including vitreomacular traction (VMT) and macular hole (MH). Both conditions can present with metamorphopsia and decreased vision. In cases of symptomatic VMT and full-thickness macular hole, pars plana vitrectomy has long been the standard of care...
October 27, 2016: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/27779685/identification-of-potential-biomarkers-and-drugs-for-papillary-thyroid-cancer-based-on-gene-expression-profile-analysis
#4
Ting Qu, Yan-Ping Li, Xiao-Hong Li, Yan Chen
The present study aimed to systematically examine the molecular mechanisms of papillary thyroid cancer (PTC), and identify potential biomarkers and drugs for the treatment of PTC. Two microarray data sets (GSE3467 and GSE3678), containing 16 PTC samples and 16 paired normal samples, were downloaded from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) were identified using the Linear Models for Microarray Analysis package. Subsequently, the common DEGs were screened for functional and pathway enrichment analysis using the Database for Annotation Visualization and Integrated Discovery...
October 19, 2016: Molecular Medicine Reports
https://www.readbyqxmd.com/read/27688592/release-of-experimental-retinal-vein-occlusions-by-direct-intraluminal-injection-of-ocriplasmin
#5
Marc D de Smet, Jean Marie Stassen, Thijs C M Meenink, Tom Janssens, Valérie Vanheukelom, Gerrit J L Naus, Maarten J Beelen, Bart Jonckx
PURPOSE: Retinal vein occlusions (RVO) are a major cause of vision loss in people aged 50 years and older. Current therapeutic options limit the consequences of RVO but do not eliminate the cause. Cannulation of the involved vessel and removal of the clot may provide a more permanent solution with a less demanding follow-up. However, cannulation of smaller retinal veins remains challenging. This paper explores the use of ocriplasmin (recombinant plasmin without its kringles) to clear RVO, using a robotic micromanipulator...
September 28, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27681001/treatment-of-vitreomacular-traction-with-intravitreal-perfluoropropane-c3f8-injection
#6
Nathan C Steinle, Dilsher S Dhoot, Carlos Quezada Ruiz, Alessandro A Castellarin, Dante J Pieramici, Robert F See, Steven C Couvillion, Maʼan A Nasir, Robert L Avery
PURPOSE: To assess the posterior vitreous release rates following a single, office-based intravitreal injection of expansile gas in treating vitreomacular traction. METHODS: Thirty eyes of 29 consecutive patients with symptomatic vitreomacular traction received a single, office-based intravitreal injection of up to 0.3 mL of 100% perfluoropropane (C3F8). RESULTS: Overall, vitreomacular traction release occurred in 25 of 30 eyes by the final follow-up visit (83% final release rate); furthermore, 90% (9 of 10 eyes) with diabetes mellitus released, 83% (5 of 6 eyes) with concurrent epiretinal membrane released, and 83% (5 of 6 eyes) previously treated with ocriplasmin released...
September 27, 2016: Retina
https://www.readbyqxmd.com/read/27619226/ocriplasmin-for-treatment-of-vitreomacular-traction-an-update
#7
Mohammed Ali Khan, Julia A Haller
Pharmacologic vitreolysis with ocriplasmin, a 27 kilodalton serine protease, is an effective nonsurgical treatment option for vitreomacular traction (VMT). Data from phase III clinical studies, including the Microplasmin for Intravitreal Injection-Traction Release without Surgical Treatment (MIVI-TRUST) and Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) studies, have demonstrated the treatment efficacy of ocriplasmin for VMT and full-thickness macular hole (FTMH)...
September 12, 2016: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/27589049/real-world-outcomes-of-ocriplasmin-use-by-members-of-the-british-and-eire-association-of-vitreoretinal-surgeons
#8
R J Haynes, D Yorston, D A H Laidlaw, J Keller, D H W Steel
PurposeTo describe a survey of the use of ocriplasmin by members of the British and Eire Association of VitreoRetinal Surgeons (BEAVRS) for VitreoMacular Traction (VMT) and Full Thickness Macular Hole (FTMH) and compare it to published MIVI TRUST trial data.MethodsAll 173 BEAVRS members were contacted by email in October 2014 requesting data on all cases treated with ocriplasmin up to that date. The total number of cases, FTMH closure rate, VMT release rate and the frequency of adverse events were recorded...
September 2, 2016: Eye
https://www.readbyqxmd.com/read/27548448/baseline-predictors-of-vitreomacular-adhesion-traction-resolution-following-an-intravitreal-injection-of-ocriplasmin
#9
Timothy L Jackson, Carl D Regillo, Aniz Girach, Pravin U Dugel
BACKGROUND AND OBJECTIVE: To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA). PATIENTS AND METHODS: Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 µg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and non-surgical FTMH closure [month 6])...
August 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27499517/results-of-the-2-year-ocriplasmin-for-treatment-for-symptomatic-vitreomacular-adhesion-including-macular-hole-oasis-randomized-trial
#10
Pravin U Dugel, Michael Tolentino, Leonard Feiner, Petra Kozma, Annick Leroy
PURPOSE: The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial was designed to evaluate the long-term efficacy and safety profile of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction, including full-thickness macular hole (FTMH). DESIGN: Phase 3b, randomized, sham-controlled, double-masked, multicenter clinical trial. PARTICIPANTS: Sample size was 220 subjects (146 ocriplasmin, 74 sham) randomized in a 2:1 ratio to receive intravitreal ocriplasmin 0...
October 2016: Ophthalmology
https://www.readbyqxmd.com/read/27444007/-pharmaological-vitreolysis-with-ocriplasmin-as-a-treatment-option-for-symptomatic-focal-vitreomacular-traction-with-or-without-macular-holes-%C3%A2-400%C3%A2-%C3%AE-m-compared-to-tranconjunctival-vitrectomy
#11
M Maier, S Abraham, C Frank, C P Lohmann, N Feucht
BACKGROUND: To evaluate the resolution rate in patients with symptomatic vitreomacular traction (VMT) ≤ 1500 μm with or without macular holes ≤ 400 μm after therapy with intravitreal ocriplasmin (Jetrea®) injections in a clinical setting in comparison to transconjunctival vitrectomy. MATERIALS AND METHODS: We examined 21 eyes of 21 consecutive patients with vitreomacular traction with or without macular holes who underwent intravitreal injection of 0...
July 21, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/27438077/the-portuguese-experience-with-ocriplasmin-in-clinical-practice
#12
João Figueira, David Martins, Bernardete Pessoa, Natália Ferreira, Angelina Meireles, António Sampaio, Ângela Carneiro, Fernanda Vaz, João Nascimento, Natacha Moreno, José Roque, Manuel Domingues, Rita Flores, Carla Teixeira, Eduardo Conde, Filipe Henriques, Helena Proença, José Pita Negrão, Marisa Barbosa, Rufino Silva, Sara Vaz-Pereira, Pedro Pereira Neves, Nuno Gomes, Miguel Raimundo
AIM: Evaluate the real-life experience with ocriplasmin on vitreomacular traction (VMT) release and full-thickness macular hole (FTMH) closure in Portugal. METHODS: Multicentric, retrospective study of 83 eyes of 78 patients who were treated with intravitreal ocriplasmin for VMT with and without FTMH. Primary outcomes were VMT release and FTMH closure. Secondary outcomes included visual acuity changes and structural features on spectral-domain ocular coherence tomography...
2016: Ophthalmic Research
https://www.readbyqxmd.com/read/27430356/functional-improvement-assessed-by-multifocal-electroretinogram-after-ocriplasmin-treatment-for-vitreomacular-traction
#13
Settimio Rossi, Francesco Testa, Paolo Melillo, Ada Orrico, Michele Della Corte, Francesca Simonelli
BACKGROUND: To evaluate the functional recovery of patients with symptomatic vitreomacular traction (VMT) after Ocriplasmin treatment. METHODS: Prospective, single centre, consecutive case series. Patients were treated with a single intravitreal injection of Ocriplasmin (Jetrea, Thrombogenics Inc, USA, Alcon/Novartis EU). The following outcome measures are considered: resolution of VMT, evaluated through the use of optical coherence tomography (SD-OCT), functional recovery evidenced by multifocal-electroretinogram (mfERG) and microperimetry (MP1) after treatment with Ocriplasmin...
2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27429719/cost-effectiveness-of-ocriplasmin-for-the-treatment-of-vitreomacular-traction-and-macular-hole
#14
Craig Bennison, Stephanie Stephens, Benedicte Lescrauwaet, Ben Van Hout, Timothy L Jackson
BACKGROUND: If left untreated, vitreomacular traction (VMT) will infrequently improve through spontaneous resolution of vitreomacular adhesion (VMA), and patients remain at risk of further deterioration in vision. The mainstay of treatment for VMT is vitrectomy, an invasive procedure that carries the risk of rare but serious complications and further vision loss. As such, a 'watch and wait' approach is often adopted before this surgical intervention is performed. Ocriplasmin (microplasmin) is a potential alternative treatment for patients with symptomatic VMT that may remove the requirement for vitrectomy...
2016: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/27388220/from-the-analysis-of-pharmacologic-vitreolysis-to-the-comprehension-of-ocriplasmin-safety
#15
Francesco Morescalchi, Elena Gambicorti, Sarah Duse, Ciro Costagliola, Francesco Semeraro
INTRODUCTION: Pharmacologic vitreolysis is a strategy used to treat anomalous posterior vitreous detachment, by weakening vitreoretinal adhesion with an intravitreal drug. Pharmacologic vitreolysis facilitates surgery, and abnormalities of the vitreoretinal interface including vitreomacular traction (VMT) and early stage macular hole (MH) could be resolved. Ocriplasmin is a recombinant protease, active against fibronectin and laminin, which are important components of the vitreoretinal interface...
September 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27341665/ellipsoid-zone-mapping-and-outer-retinal-characterization-after-intravitreal-ocriplasmin
#16
Yuji Itoh, Justis P Ehlers
PURPOSE: To assess outer retinal architectural alterations after intravitreal ocriplasmin with a novel automated ellipsoid zone (EZ) mapping algorithm. METHODS: A single-center, retrospective, consecutive case series of image analysis was performed. Quantitative assessment of EZ status imaged with spectral-domain optical coherence tomography was performed before and after single intravitreal injection of 0.125 mg of ocriplasmin (Jetrea, Thrombogenics). A novel EZ mapping algorithm was used to assess the EZ retinal pigment epithelium (RPE) central area, EZ-RPE macular volume, and en face EZ integrity based on the percentage of sampling areas with 20 μm or greater EZ-RPE thickness...
December 2016: Retina
https://www.readbyqxmd.com/read/27278373/rhegmatogenous-retinal-detachment-following-intravitreal-ocriplasmin
#17
Haifa A Madi, Richard J Haynes, Diana Depla, Morten D de la Cour, Sarit Lesnik-Oberstein, Mahi M K Muqit, Niall Patton, Nick Price, David H W Steel
PURPOSE: To describe the characteristics and outcomes of patients presenting with rhegmatogenous retinal detachment (RRD) after ocriplasmin (OCP) injection. METHODS: Retrospective, multi-centre, observational case series with case note review. RESULTS: Eight patients with symptomatic vitreomacular traction (six with concomitant macular hole) were diagnosed with RRD after a median of 16 days (range 3-131 days) post-OCP injection. Presentation was within 3 weeks of the OCP injection in six of the cases...
December 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27262728/ocriplasmin-variable-efficacy
#18
EDITORIAL
David H W Steel, David Wong
No abstract text is available yet for this article.
July 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27224069/initial-experience-with-ocriplasmin-in-the-treatment-of-vitreomacular-traction
#19
José Maurício Botto de Barros Garcia, David Leonardo Cruvinel Isaac, Marcos Ávila
This study aimed to report the clinical and structural outcomes of intravitreal ocriplasmin in the treatment of vitreomacular interface disorders in two tertiary centers in Brazil. A retrospective study was performed by reviewing medical records and spectral domain optical coherence tomography (SD-OCT) findings of seven patients who were treated with a single ocriplasmin injection. A total of 57.14% of patients achieved resolution of vitreomacular traction as evidenced by SD-OCT. Regarding our functional results, 87...
April 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/27187883/-therapeutic-options-in-vitreomacular-traction-with-or-without-a-macular-hole
#20
M Maier, S Abraham, C Frank, C P Lohmann, N Feucht
Treatment is usually indicated for symptomatic vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) and without spontaneous resolution. Ultrastructural parameters are evaluated by SD-OCT, in order to classify the vitreoretinal interface and to estimate the success rate of treatment. The resolution rate after therapy with intravitreal Jetrea® (Ocriplasmin) is high (up to 70 %) in patients with symptomatic focal vitreomacular traction (≤ 1500 µm) with or without a macular hole (≤ 250 µm) and with no epiretinal membrane (ERM), but depends on the exact baseline analysis...
May 2016: Klinische Monatsblätter Für Augenheilkunde
keyword
keyword
55513
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"